FDA Requires Makers of Zolpidem(Drug information on zolpidem) to Decrease Recommended Dosage
The FDA has issued a Drug Safety Communication requiring manufacturers of brand name and generic forms of the insomnia drug zolpidem (Ambien) to decrease the recommended dosage. This communication comes in response to reports that levels of the drug left in the blood the morning after use may be enough to impair activities, such as driving. Physicians are urged to caution all patients currently taking these medications about next-morning impairment.
View the full Drug Safety Communication, here.
